scispace - formally typeset
H

Harlan M. Krumholz

Researcher at Yale University

Publications -  1966
Citations -  177853

Harlan M. Krumholz is an academic researcher from Yale University. The author has contributed to research in topics: Myocardial infarction & Population. The author has an hindex of 85, co-authored 1826 publications receiving 159216 citations. Previous affiliations of Harlan M. Krumholz include Veterans Health Administration & Robert Wood Johnson Foundation.

Papers
More filters
Journal ArticleDOI

The Impact of Venous Thromboembolism on Risk of Death or Hemorrhage in Older Cancer Patients

TL;DR: Concomitant VTE is not only a marker and potential mediator of increased risk of death among older cancer patients, but patients with a VTE have a marked increasedrisk of major hemorrhage.
Journal ArticleDOI

The China Patient-Centered Evaluative Assessment of Cardiac Events (China PEACE) Retrospective Study of Acute Myocardial Infarction: Study Design

TL;DR: The first study from China PEACE, the Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), is designed to promote improvements in acute myocardial infarction quality of care by generating knowledge about the characteristics, treatments, and outcomes of patients hospitalized with AMI across a representative sample of Chinese hospitals during the past decade.
Journal ArticleDOI

Hospital Collaboration with Emergency Medical Services in the Care of Patients with Acute Myocardial Infarction: Perspectives from Key Hospital Staff

TL;DR: hospital staff from higher-performing hospitals described broad, multifaceted strategies to support collaboration with EMS in providing acute myocardial infarction care, and the association of these strategies with hospital performance should be tested quantitatively in a larger representative study.
Journal ArticleDOI

Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.

TL;DR: A dose-response relationship between higher doses and lower mortality is observed, and future studies will need to determine whether this association is causal.
Journal ArticleDOI

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.

TL;DR: Although cardiovascular surrogate outcomes trials frequently show superiority of the tested intervention, they are infrequently followed by a prominent outcomes trial, and may be more appropriate for excluding benefit from the patient perspective than for identifying it.